Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pomerantz LLP is investigating claims on behalf of ... (NASDAQ: VTAE ).  Such investors are advised ... rswilloughby@pomlaw.com or 888-476-6529, ext. 237. The ... and/or directors have violated Sections 10(b) and 20(a) of ... On February 27, 2015, the Company announced that its ...
(Date:2/27/2015)... N.J. , Feb. 27, 2015  Acsis Inc., ... and serialization solutions, announced today that John DiPalo ... a Supply & Demand Chain Executive 2015 ... executives who are leading initiatives to help prepare their ... of today,s business climate. This year,s list of Provider ...
(Date:2/27/2015)... - La ... monitoraggio dell,infarto congestizio (CHF - Congestive Heart Failure) ...   Vectorious Medical Technologies, società ... il monitoraggio cardiaco destinato a pazienti affetti da ... concluso una raccolta di finanziamenti per 5 milioni ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2
... NOVATO, Calif., Nov. 21, 2011 Ultragenyx Pharmaceutical, ... for rare and ultra-rare genetic disorders, today announced ... Chief Business Officer. Mr. Kassberg will be responsible ... strategic planning activities, as well as the human ...
... Nov. 21, 2011 Reportlinker.com announces that a ... catalogue: Medical Automation Technologies, Products ... REPORT SCOPE ... Since the enactment of the ...
Cached Medicine Technology:Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 2Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 3Ultragenyx Appoints Tom Kassberg as Chief Business Officer and Announces Management Team 4Medical Automation Technologies, Products and Markets 2Medical Automation Technologies, Products and Markets 3Medical Automation Technologies, Products and Markets 4Medical Automation Technologies, Products and Markets 5Medical Automation Technologies, Products and Markets 6Medical Automation Technologies, Products and Markets 7Medical Automation Technologies, Products and Markets 8Medical Automation Technologies, Products and Markets 9Medical Automation Technologies, Products and Markets 10Medical Automation Technologies, Products and Markets 11Medical Automation Technologies, Products and Markets 12Medical Automation Technologies, Products and Markets 13Medical Automation Technologies, Products and Markets 14Medical Automation Technologies, Products and Markets 15
(Date:2/27/2015)... Hills, CA (PRWEB) February 27, 2015 ... Wolf, LLP (BPW) has been chosen as their doc-link ... Dynamics GP, CRM and other complimentary solutions for their ... in working with credit unions. Altec and BPW have ... leveraging doc-link’s integration to Dynamics GP. , “We are ...
(Date:2/27/2015)... Evans, GA (PRWEB) February 27, 2015 In honor ... Center for Primary Care (CPC) South office, is offering tips on ... leading cause of death, but that doesn't mean people have to ... to change some risk factors — such as family history, sex ... to take. , Dr. Scott has six helpful tips to ...
(Date:2/27/2015)... The V Foundation for Cancer Research, one ... excited to announce numerous promotions taking place this March. ... partnerships highlight The V Foundation’s significant work in the ... all to get involved. Awarding 100 percent of ... V Foundation has funded more than $130 million in ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Dr. Andrew ... surgeons , is pleased to announce the expansion of ... open in Delafield. Quintessa has begun seeing patients on ... new Delafield location will offer a variety of state-of-the-art ... Botox, filler injectables, micro laser peels, chemical peels, microdermabrasion, ...
(Date:2/27/2015)... February 27, 2015 Legislation passed ... includes a pharmacy provision to help prevent inappropriate ... pharmacy counter. The Protecting the Integrity of Medicare ... Subcommittee Chairman Kevin Brady (R-TX) and Ranking Member ... the prescription drug abuse epidemic and implement the ...
Breaking Medicine News(10 mins):Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 2Health News:Altec Announces 2014 doc-link for Dynamics Partner of the Year Award Recipient 3Health News:Center for Primary Care Celebrates American Heart Month 2Health News:Center for Primary Care Celebrates American Heart Month 3Health News:Center for Primary Care Celebrates American Heart Month 4Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2
... , ... ... ... ...
... is not well controlled and on low doses of ... most effective of three possible step-up treatments. National Jewish ... and Lynn Taussig, and colleagues in the NIH-funded Childhood ... 2, 2010, online in the New England Journal ...
... them would lower people,s quality of life, , TUESDAY, March ... caused by kidney failure yield mixed results, depending on the ... People on dialysis with severe anemia, according to the study, ... drugs -- known as erythropoiesis-stimulating agents (ESAs) and marketed as ...
... ... ... ... ...
... ... ... , , ... ...
... eye-opening editorial in the March 2010 issue of the ... Beryl Benacerraf, MD, urges the medical community to use ... imaging test for better diagnosis capability in the evaluation ... the editorial, "Why Has Computed Tomography Won and Ultrasound ...
Cached Medicine News:Health News:Vitamin Shoppe, Inc. To Present at the 2010 Stifel Nicolaus Consumer Conference 2Health News:Vitamin Shoppe, Inc. To Present at the 2010 Stifel Nicolaus Consumer Conference 3Health News:Long-acting beta-agonists most effective step-up therapy for children with poorly controlled asthma 2Health News:For Some on Dialysis, Anemia Drugs Pose Risks 2Health News:For Some on Dialysis, Anemia Drugs Pose Risks 3Health News:For Some on Dialysis, Anemia Drugs Pose Risks 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 2Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 3Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 4Health News:New Data from Caldolor(R) Study in Burn Patients to be Presented at 42nd Annual Meeting of The American Burn Association 5Health News:AMA Honors Iowa State Representative Mark Smith With Top Government Service Award 2Health News:AMA Honors Iowa State Representative Mark Smith With Top Government Service Award 3Health News:Why do physicians order costly CTs? Ultrasound yields better diagnosis, safer, less costly 2
... aluminum cuffs that can be bent to ... joint alignment, unique slot/screw adjustment mechanism allows ... cuff position. Cuffs are configured to offer ... with contractures.,The hinge can be locked in ...
... ACTION Elbow Wrap replaces messy taping and ... and others experiencing epicondylitis. Preferred by doctors ... non-bulky fit. Two overlay straps allow you ... foam lining holds the Elbow Wrap comfortably ...
... is designed to handle post-op elbow arthroscopy, ... Bledsoe Extender Arm Brace should be used ... the elbow is desired. In most cases, ... formed, fitted and adjusted in 5 minutes ...
... contour design of this lightweight brace allows it ... It stabilizes the ankle joint following severe sprains, ... semi-rigid spiral stays move with the ankle and ... help the splint control rotational strains on the ...
Medicine Products: